HighTower Advisors LLC Decreases Position in Alnylam Pharmaceuticals, Inc. (ALNY)

HighTower Advisors LLC trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 20.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,900 shares of the biopharmaceutical company’s stock after selling 1,017 shares during the period. HighTower Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $311,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ALNY. BlackRock Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 34,755.2% during the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares in the last quarter. FMR LLC raised its holdings in shares of Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after buying an additional 815,270 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after buying an additional 759,295 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 305.0% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 508,852 shares of the biopharmaceutical company’s stock valued at $40,586,000 after buying an additional 383,214 shares in the last quarter. Finally, PDT Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $23,537,000. 94.25% of the stock is currently owned by institutional investors.

A number of equities analysts recently weighed in on the company. Goldman Sachs Group, Inc. (The) raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $62.00 to $163.00 in a report on Monday, October 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $124.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, September 25th. Jefferies Group LLC lifted their price target on Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, September 26th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $83.00 price target (up from $56.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 20th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $116.00 price target (up from $110.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 20th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $100.80.

ILLEGAL ACTIVITY NOTICE: “HighTower Advisors LLC Decreases Position in Alnylam Pharmaceuticals, Inc. (ALNY)” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://transcriptdaily.com/2017/10/23/hightower-advisors-llc-decreases-position-in-alnylam-pharmaceuticals-inc-alny.html.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 114.70 on Monday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $31.38 and a 52-week high of $126.16. The company’s market capitalization is $10.52 billion. The company’s 50 day moving average price is $105.19 and its 200 day moving average price is $79.74.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. During the same period last year, the company earned ($1.05) EPS. The firm’s revenue for the quarter was up 82.9% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.20) EPS for the current year.

In related news, President Barry E. Greene sold 76,815 shares of the stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now owns 165,399 shares of the company’s stock, valued at $16,539,900. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, President Barry E. Greene sold 85,316 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total value of $10,664,500.00. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply